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Studying teratogenic effectS of 
medication uSe during pregnancy: 
challengeS and pitfallS
M. Van Gelder*
Department for Health Evidence, Radboud University Nijmegen 
Medical Centre, Nijmegen, the Netherlands
Summary: Depending on the data sources used and the types of stud-
ies included, 29% to 99% of pregnant women in developed countries 
take at least 1 prescribed drug. Although some drugs, such as thalido-
mide and isotretinoin, are classical examples of human teratogens 
(nongenetic risk factors that cause birth defects), the human terato-
genic risks are undetermined for > 90% of prescription drug treat-
ments approved for marketing in the United States since 1980. Due 
to this lack of information, adherence to pharmacologic treatment 
may be discouraged, which may endanger maternal and fetal health, 
or women may choose to terminate their wanted pregnancies based 
on fear of adverse effects. In other pregnancies, fetal development 
may be disturbed by unknown teratogenic exposures that could have 
been avoided. Therefore, high-quality human studies focusing on 
the adverse effects of medication use during pregnancy are urgently 
needed. However, apart from the general methodologic problems in 
epidemiologic research, such as confounding, selection and informa-
tion bias, and limitations in making causal inferences, pharmacoepi-
demiologic studies focusing on birth defects face some important 
problems that are unique to this area of research. During this lecture, 
these problems and some new initiatives in epidemiologic research on 
adverse effects of medication use during pregnancy will be discussed.
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prediction of pharmacological effectS 
of cnS-active agentS during early phaSeS 
of drug development
J. Van Gerven*
Centre for Human Drug Research, Leiden, the Netherlands
Summary: In the last decades, several drugs for neuropsychiatric 
indication failed in late stages of development or were withdrawn 
shortly after launch, including disease-modifying compounds for 
dementia (eg, the γ -secretase inhibitor tarenflurbil) and innovative 
drugs for smoking addiction (eg, the CB1-antagonist rimonabant). A 
few years ago, some of the larger pharmaceutical industries decided 
that the financial risk of developing drugs for psychiatric indications 
was too large, and many CNS projects were abandoned. Currently, 
the industry tries to innovate CNS drug development by investing in 
partnerships with expert groups and exploring novel science-driven 
approaches. An essential requirement for a successful drug is that it 
reaches its therapeutic target in the right concentrations during the 
correct time period, and that it avoids levels or targets associated with 
adverse events. In addition, the drug’s mechanism of action needs to 
have a beneficial effect on the pathogenesis or pathophysiology of 
the disease. Most of these aspects can be accurately determined in 
healthy subjects, in the earliest phases of drug development. To some 
extent this also includes indications of therapeutic benefit, because 
many diseases involve well-known physiological processes that are 
also measurable in normal subjects, although therapeutic benefit can 
only be reliably examined in patients. Thus, the predictions of the 
optimal dosing regimen (or the likeliness of failure) of a new drug in 
patients can be significantly enhanced by demonstration of optimal 
pharmacologic activity in every early (and later) study during drug 
development. This lecture will provide several examples, in which 
pharmacologic effect measurements were incorporated into “tradi-
tional” single and multiple ascending dose studies in Phase I. These 
instruments include (but are not limited to) validated effect biomark-
ers such as the NeuroCart CNS test battery (pharmacologic activity 
and beneficial/detrimental effects), PET measurements or continu-
ous CSF-sampling (BBB-penetration), pharmacologic challenge tests 
(pharmacologic activity) or informative positive controls (bench-
marking), and pharmacokinetic/dynamic analysis for data integra-
tion. The examples involve innovative compounds such as partial 
GABA-A-agonists and CB1-antagonists, and the first human studies 
with a fast-dissociating D2-antagonist and an orexin half-antagonist. 
In most of these cases, traditional approaches were misleading, but a 
goal-directed “question-based” application of pharmacologic tools 
in healthy subjects demonstrated brain penetration and meaningful 
functional effects (indicative of therapeutic or detrimental activity), 
which contributed to accurate predictions of therapeutic windows 
in clinical trials.
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induStry iS more fit for clinical trialS 
than academy
A. Vas*
Head Office, Gedeon Richter Plc, Budapest, Hungary
Summary: Drug R&D is costly, time-consuming, and has a low suc-
cess rate. The costs exceed 1 billion USD. From the human Phase 
I trial on, the increase is exponential. In the EU, 60% of clinical 
trials applied for every year are sponsored by the pharmaceutical 
industry and 40% by other stakeholders, such as academics. It is 
no wonder, then, that the EU Clinical Trials Directive 2011/20/EC 
incented protest mainly from the academic and SME stakeholders. 
According to the EC, although the Directive brought about impor-
tant improvements in the safety and ethical soundness of clinical 
trials and in the reliability of clinical trials data, on the other hand, 
it led to the fall of the number of applications by 25%. The costs 
have increased. The staff needs for industry sponsors to handle the 
clinical trial authorization process have doubled, with SMEs facing 
an even sharper increase. For noncommercial sponsors, the increase 
in administrative requirements has led to a 98% increase in admin-
istrative costs. Insurance fees have increased by 800% for industry 
sponsors. Although the EC is now about to ease the burdens, it is 
clear that significant resources would be required anyhow. The proper 
and time-conscious conduct of extended, multinational, cross-conti-
nental clinical studies requires sufficient high-quality staff, logistics, 
experience, and knowledge of different regulatory aspects, let alone 
a sound financial background. This can be handled only by the help 
of industry resources at the end. Trends and data underpinning this 
opinion will be demonstrated in the presentation.
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collection and impact of patient 
reported outcomeS
A. Viola*
Unité de Pharmaco-Epidémiologie de Lyon, UCBL/CHU de Lyon, 
Lyon, France
Summary: The efficacy assessment in clinical studies evaluating drug 
effects, or more generally disease management, is generally focused 
on the occurrence of objective clinical or economical outcomes, in 
line with regulatory guidelines. However, there is growing recogni-
tion of the value of capturing wider effects of treatments reported by 
patients in the form of patient-reported outcomes (PROs). A PRO 
is defined as any report of the status of a patient’s health condition 
that comes directly from the patient, without interpretation of the 
patient’s response by a clinician or anyone else. After examining the 
reasons explaining the development of these new clinical research 
clinical therapeutics
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outcomes, the main fields covered by PROs (such as quality of life) in 
chronic diseases will be described. We will develop PRO measurement 
issues, notably psychometric properties and cultural adaptations, and 
also differences between generic and disease-specific instruments, 
with quality of life instruments as an example. Then we will define 
the use of PROs data in the field of adherence research, with their 
advantages and limitations compared with other sources of data. 
Last, the actual or potential impact of PROs will also be examined in 
terms of quality of care for daily medical practice and research issues.
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clinical pharmacology in health  
care in croatia
V. Vlahovic-Palcevski1,2*
1Unit for Clinical Pharmacology, University Hospital Rijeka; 
and 2Department of Pharmacology, University of Rijeka Medical 
School, Rijeka, Croatia
Summary: The new manifesto on clinical pharmacology (CP) empha-
sizes the importance of CP in delivery of health care, the role of CP 
that has not always been played the way and in the extent it was 
hoped for. In Croatia, CP has been recognized as a separate medical 
discipline/specialty since 1974. Since then, > 30 physicians have been 
trained in CP and work in various health care settings across country. 
Depending on the setting, they provide CP services, conduct research, 
and are involved in teaching. In some settings, clinical pharmacolo-
gists provide direct patient care, having a direct responsibility for 
patients, but more commonly provide a range of services to clinical 
colleagues and their patients as well as serve as consultants in regula-
tory and administrative bodies dealing with medications. Although 
specialists in CP, not all clinical pharmacologists involved in health 
care belong to established departments/units of CP. Differences in 
organizational models for delivering CP services to health care prob-
ably arise from not adequately defined functions of CP. The functions 
have been well defined in the new Manifesto but not well recognized 
by relevant bodies. We should not be ignoring the challenging future 
of CP in health care.
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the ScottiSh model: ScottiSh medicineS 
conSortium (Smc)
D.J. Webb*
Pharmacology Toxicology & Therapeutics, University of 
Edinburgh, Edinburgh, United Kingdom
Summary: UK health care is provided by a national health service 
(NHS), within which medicines are a major and growing cost. 
Concerns from patients, politicians, medical practitioners, and the 
press about “postcode” prescribing (marked regional differences 
in availability of newly licensed medicines) led to the creation of 
the Scottish Medicines Consortium (SMC). Run by NHS clini-
cians, SMC provides rapid advice on all new medicines, including 
new indications/formulations for existing therapies. A streamlined 
2-stage pharmacy and health economic, and then strategic, review 
of submissions from industry by SMC provides an objective review 
of the data and a wider societal view of need. A patient perspec-
tive is included. Comparative cost-effectiveness is assessed, prefer-
ably by using QALY ICERs, and advice given close to UK licensing 
(usually within 4 months). This early advice means that physicians 
are prepared to wait for the decision from SMC, and prescribing 
is relatively uncommon outside the guidance. Three outcomes are 
possible: (1) accept for general use; (2) accept with restriction (by 
specialist prescriber, or only for a subgroup within the license); or 
(3) do not recommend for use in Scotland. Appeals can be heard and 
resubmissions can be made if the evidence base changes. Around 
1000 submissions have now been made, including abbreviated sub-
missions for minor license changes, since 2002. Around two thirds of 
all medicines were accepted for use in NHS Scotland but many in a 
way more restrictive than the license. Around 50% of resubmissions 
are accepted. Evidence suggests SMC decisions are not influenced by 
budget impact (affordability) but are strongly influenced by whether 
the drug provides value for money to the NHS in Scotland. Accepted 
modifiers of decisions include orphan indications, end-of-life treat-
ment, bridging to a definitive treatment, and the development of 
licensed treatment where only an unlicensed preparation previously 
existed. Drug utilization data suggest that early advice influences 
prescribing patterns, in a positive way for approved drugs, and by 
lack of uptake (or reduction of existing prescribing) for those not rec-
ommended (with some exceptions). Benchmarking shows a high level 
of consistency with subsequent decisions from the National Institute 
for Health and Clinical Excellence (NICE), and the Pharmaceutical 
Benefits Advisory Committee (PBAC) in Australia. SMC has an ongo-
ing horizon scanning program, created a Scottish Management of 
Antimicrobial Resistance action Plan (ScotMARAP; 2008), and now 
runs a Patient Access Scheme to make high-cost drugs affordable 
to Scottish patients. An open and inclusive process, involving key 
stakeholders, can produce useful, rigorous, evidence-based advice 
to a health care system in a way that is acceptable to the NHS and to 
the pharmaceutical industry, and occurs sufficiently early after the 
launch of a new drug to inform and influence subsequent prescrib-
ing patterns.
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new medicineS for control and 
elimination of malaria
T.N.C. Wells*
Research and Development, Medicines for Malaria Venture MMV, 
Geneva, Switzerland
Summary: Despite being 1 of the most prevalent tropical diseases, for 
many years malaria was not a commercial priority for the pharma-
ceutical industry. However, in response to the emergence and spread 
of resistance to the available antimalarial drugs, there has been a 
renaissance in the discovery and development of new medicines to 
control the disease in the last few years. The persistent threat of 
resistance means that new molecules with novel mechanisms of action 
are continually required. Furthermore, the recent call for the elimi-
nation and eradication of malaria has prompted an extension of the 
stages of the life cycle of malaria parasites that should be targeted 
by new molecules. Recent advances in genome-based technologies 
and in vitro screening of whole parasites have broadened the range 
of therapeutic targets and are accelerating the development of a new 
generation of treatments for both malaria control and eradication.
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networking for regulatory toxicology
M. Wilks*
Swiss Centre for Applied Human Toxicology, University of Basel, 
Basel, Switzerland
Summary: The purpose of regulatory toxicology is to evaluate all 
available information relevant to the toxicity of agents, which may 
be biological, chemical, or physical in nature, on behalf of govern-
mental or international organizations. The aim is to protect workers, 
consumers, the public generally, and the environment. Wherever pos-
sible, this is done through a process of quantitative or qualitative risk 
